Kalytera Therapeutics, Inc.

Kalytera Therapeutics, Inc.

January 11, 2017 08:39 ET

Kalytera Therapeutics, Inc. Grants Stock Options

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 11, 2017) - Kalytera Therapeutics, Inc. (the "Company" or "Kalytera") (TSX VENTURE:KALY) announces that it has granted stock options on January 9, 2017 to purchase 170,466 common shares of the Company to a director. The stock options have an exercise price of $0.52 per common share and expire ten years from the date of grant. One-third of the options granted will vest on December 30, 2017 and the remaining options will vest in twenty-four (24) equal monthly installments commencing January, 2018.

About Kalytera Therapeutics

Kalytera is pioneering the development of a next generation of cannabinoid therapeutics. Through its proven leadership, drug development expertise, and intellectual property portfolio, Kalytera seeks to establish a leading position in the development of novel cannabinoid medicines for a range of important unmet medical needs.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Kalytera Therapeutics, Inc.
    Robert Farrell
    CFO, COO & President
    (888) 861-2008